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Abstract
This guideline aims to describe the complement system and the functions of the constituent pathways, with particular focus on
primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate
immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways
within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3.
Complement deficiencies account for ~5% of PIDs. The clinical consequences of inherited defects in the complement system are
protean and include increased susceptibility to infection, autoimmune diseases (e.g., systemic lupus erythematosus), age-related
macular degeneration, renal disorders (e.g., atypical hemolytic uremic syndrome) and angioedema.Modern complement analysis
allows an in-depth insight into the functional and molecular basis of nearly all complement deficiencies. However, therapeutic
options remain relatively limited for the majority of complement deficiencies with the exception of hereditary angioedema and
inhibition of an overactivated complement system in regulation defects. Current management strategies for complement disor-
ders associated with infection include education, family testing, vaccinations, antibiotics and emergency planning.
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Introduction
Most complement deficiencies have a combined estimated
prevalence of 0.03% in the general population, meaning that
they meet the criteria for rare diseases (< 0.05% in the EU and
< 200,000 individuals in the USA [i.e., approximately <
0.06%]) [1]. A small number of deficiencies are more com-
mon: mannose-binding lectin (MBL) deficiency has a preva-
lence of ~5%, and deficiencies of C4A and C4B have preva-
lence rates of 11–22% and 30–45%, respectively [2, 3].
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Complement deficiencies collectively account for 5.2% of the
primary immunodeficiencies (PIDs) reported in the European
Society for Immunodeficiencies (ESID) Registry and may
well be underestimated partly due to a lack of readily available
laboratory testing [4, 5].
The complement system is a highly conserved part of the
innate immune system, which can be traced back as far as the
sea urchin [6]. It comprises over 30 membrane-bound and solu-
ble components and has three major functions: (1) host defense
by opsonisation, chemotaxis, induction of inflammation and lysis
of targets [7–10] (2) interfacing between innate and adaptive
immunity by augmenting the antibody response and immuno-
logical memory [11, 12] and (3) the disposal of waste through the
clearance of apoptotic cells and immune complexes [13–17].
The complement system is organized into three distinct enzy-
matic cascade pathways, namely the classical, alternative and
lectin pathways [7, 10, 13, 15, 18–20] (Fig. 1). Each of these
converge toward the cleavage of central C3 by a C3 convertase,
followed by the formation of a C5 convertase, which cleaves C5
into C5a and C5b [17, 21]. This results in activation of the
common lytic effector terminal pathway [14]. The subsequent
insertion of terminal pathway components into the cell wall leads
to lysis via the membrane attack complex (MAC), which is com-
posed of complement proteins C5b–9 [15, 17, 21, 22]. This can
occur in both bacterial and human cells, e.g., cancer cells, and, in
turn, leads to the release of biologically active fragments that
enhance inflammation, recruit leukocytes and promote host de-
fense [13, 23]. These proinflammatory cascades require strict
control by a range of soluble and membrane-bound regulatory
proteins that act to limit complement-mediated damage to the
host [10, 15, 24, 25].
The clinical consequences of inherited defects in the com-
plement system fall broadly into three areas: (1) increased
susceptibility to infection caused by encapsulated organisms,
(2) autoimmunity, in particular systemic lupus erythematosus
(SLE) [26] and (3) hyperactivation due to deficiencies in reg-
ulatory proteins that result in specific disorders.
This guideline aims to describe the complement system, the
functions of the constituent pathways, regulatory proteins and
the expanding range of disorders associated with complement
defects, with particular focus on PIDs and their diagnosis and
management. It represents consensus opinions of the authors,
based on the current literature and available evidence.
The classical pathway is triggered by activation of the sub-
units of C1 (q, r and s) after binding of C1q to
immunoglobulin-G (IgG) and IgM-containing immune com-
plexes or by C-reactive protein (CRP). The lectin pathway is
activated by the interaction of a protein molecule (MBL,
collectin-10, collectin-11, ficolin-1, ficolin-2 or ficolin-3) with
carbohydrate residues on bacterial surfaces. This results in the
activation of MBL-associated serine protease 1 (MASP1) and
MASP2. The alternative pathway is continuously undergoing
low grade spontaneous activation “tick over” through a feed-
back loop involving hydrolysis of C3 and may also be trig-
gered by LPS derived fromGram negative bacteria. Themem-
brane attack complex (MAC) is formed by the sequential as-
sembly of C5b, C6, C7, C8 andmany copies of C9 into a pore.
Assessment of the Complement System
The first tier of complement system assessment is to carry out
functional assays that are specific for each activation arm. By
performing assays relating to the classical, alternative and lec-
tin pathways, it is possible to screen for and narrow down the
possible deficiencies [18, 27]. Following detection of absent
or low activity in one or more pathways, the search can be
focused on specific deficiencies [28]. Accordingly, the next
tier of testing is to measure the concentration and/or function
of individual components [1]. During testing, it is important to
note that complement levels reflect a balance between con-
sumption through activation and production because many are
acute phase reactants [29]. It is exceedingly rare to have more
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than one component deficient in the same individual, with the
exception of those of the lectin pathway (MBL, mannose-
binding lectin-associated serine protease 2; MASP2).
Therefore, if multiple components are low, it is possible that
sample handling was improper, a regulatory protein was defi-
cient or autoantibodies were present. Autoantibodies targeting
the complement system may need to be assessed because they
are often associated with specific diseases, e.g., anti-C1q an-
tibody is associated with hypocomplementemic urticarial vas-
culitis and/or proliferative SLE nephritis [26, 30].
The measurement of complement activation fragments
may enable complement consumption (due to overactivation)
to be distinguished from (partial) deficiency and show subtle
changes in response to complement dysregulation [30]. These
activation markers indicate which pathways are involved and
to what extent, as well as the degree of therapeutic comple-
ment inhibition. Activation markers include fragments of
components that are formed during cleavage, e.g., C3a, Bb,
complexes of the activated component and their respective
regulators, e.g., sC5b–9, and convertases that are formed by
activation [30]. The measurement of these markers is compli-
cated by short half-lives and in vitro activation; the cascade
will activate in the tube after blood draw if not promptly fro-
zen at − 80 °C [31]. Samples should therefore be frozen within
2 h. This makes pre-analytical specimen handling critical for
complement analysis. Ethylenediaminetetraacetic acid
(EDTA) can largely inhibit in vitro activation; however, it is
important to verify tube type by assay since samples preserved
in EDTA are not usually compatible with complement func-
tional testing. Fig. 2 shows a flow diagram outlining the steps
that should be undertaken during complement testing.
There is huge variation between laboratories with regard to
complement testing, and few standardized tests are available
(with the exception of C3 and C4 levels). Given the importance
of complement proteins in a wide range of biological systems,
effective, standardized and accessible tests are needed [28].
Nephelometric or immunoprecipitation assays are com-
monly used to measure concentrations of individual compo-
nents of the complement system. Hemolytic assays for testing
the functions of the classical pathway (CH50) and the alterna-
tive pathway (AH50) have been available for over 40 years
and are based on quantifying the amount of serum needed to
lyse 50% of a sample of erythrocytes [32]. Similar methodol-
ogy was also developed for assessment of the lectin pathway
[33]. A Slovenian study showed that patients with C2 or C8
deficiencies present with CH50 values below the lower limit
of the reference range, that homozygous mutations are asso-
ciated with lower CH50 values than heterozygous mutations
and that patients with infections have lower CH50 values than
those not exhibiting infections [34]. Patients with homozy-
gous C2 mutations consistently present with CH50 below
the lower limit of the reference range and also significantly
lower CH50 than carriers of heterozygous mutations causing
C2 deficiency [34]. Hemolytic assays are time-consuming and
have the potential to produce variable results. Methods based
on enzyme-linked immunoassay (ELISA) have therefore been
developed for all three complement pathways (i.e., the lectin
pathway as well as the classical pathway and the alternative
pathway) [32, 35, 36]. A single assessment using three en-
zyme immunoassays to test all three pathways is now com-
mercially available. Activation marker testing may be based
either on the detection of zymogen molecules and their prod-
ucts after separation by size (polyclonal antibodies are used in
this strategy) or detection of amino acid sequences that are
exposed only when the zymogen molecule is activated
(neoepitope-specific monoclonal antibodies are used for this
approach) [32]. In addition, ELISA methodology has been
harnessed to enable assessment of autoantibodies to individual
complement components. However, there is huge variation
between laboratories regarding preferred methods for comple-
ment testing, and few standardized methods have been imple-
mented widely (with the exception of tests for C3 and C4
levels). Given the importance of complement proteins in a
wide range of biological systems, effective, standardized and
accessible tests are needed [28].
Due to close associations between certain genetic variants and
complement deficiencies, genetic testing may be included in the
diagnostic work-up [1]. In particular, genetic testing can be used
for confirmation when a single component deficiency is identi-
fied from quantitative and functional tests (Fig. 2). In recent
years, diagnosis by genetic testing has become more common
[34], and it offers an alternative option where detailed functional
assays are not available or not easily accessible. However, the
genetic diagnosis of complement deficiencies is complicated and
potentially confounded by copy number variations, point muta-
tions and the presence of pseudogenes [37].
Sanger sequencing allows selective incorporation of chain-
terminating dideoxynucleotides during in vitro DNA replica-
tion and is widely used to detect single nucleotide variants.
Although Sanger sequencing is a valuable technique, relative-
ly high cost and low speed restrict its application in genetic
testing [38]. Next-generation sequencing (NGS) is advanta-
geous because it offers high-throughput, rapid and accurate
testing of multiple genes simultaneously [39]. The implemen-
tation of NGS into routine practice is challenging due to cost
to healthcare payers (though costs are steadily reducing over
time) and the difficulties in assigning pathogenicity to the
novel variants, which are identified [40]. Clincal-exome and
whole-exome sequencing are potentially useful methods for
diagnosing complement deficiencies as these permit the use of
virtual gene panels to detect clinically relevant variants and
the interpretation of the results of such panels can be updated
alongside functional data to inform the classification of novel
potentially pathogenic variants as they are discovered. Over
time, whole-genome sequencing will become more accessi-
ble, and it is likely that NGS will form an increasing part of
J Clin Immunol (2020) 40:576–591578
complement diagnostics as costs come down and access to
testing alongside appropriate bioinformatic and clinical inter-
pretative support becomes more widespread [41].
Overview of Complement Deficiencies and Diseases
Complement deficiencies make up 1–10% of all reported
PIDs, according to international registry data [1]; however,
in some national registries, the proportion is significantly
higher [34]. Table 1 outlines known complement deficiencies
and associated symptoms/disorders. Many of the deficiencies
are associated with increased susceptibility to infection (e.g.,
by encapsulated bacteria) [26]. Deficiency of early compo-
nents of the classical pathway (C1q, C1r, C1s, C2 and C4)
leads to autoimmunity, mainly [42]. Deficiency of C3 and its
regulators (factor H [FH] and I [FI]) has been associated with
severe recurrent bacterial infections and autoimmunity [43].
Genetic variants in the CFH and CFI genes that lead to
haploinsufficiency (i.e., ~50% reductions in the levels of FH
and FI) have been associated with age-related macular degen-
eration (AMD) [44, 45]. These variants underpin the complex-
ity and range of clinical manifestations, relating to both the
degree of impairment and the involvement of multiple com-
plement pathways in the pathogenesis of AMD [1, 46, 47].
Properdin and terminal component deficiencies result in an
increased risk of neisserial infections [48]. C1-INH deficiency
is not thought to be associated with increased susceptibility to
infection; however, hereditary angioedema (HAE) attacks can
be triggered by the presence of infection [49].
aHUS atypical hemolytic uremic syndrome, AMD age-
related macular degeneration, AD autosomal dominant, AR
autosomal recessive, C1-INH C1 esterase inhibitor, C3G C3
glomerulopathy, CVID common variable immunodeficiency,
DAF decay-accelerating factor, CFHR complement factor H-
related protein, GoF gain of function, HAE hereditary angio-
edema, LAD leukocyte adhesion deficiency, LFA lymphocyte
function-associated antigen 1,MASPmannose-associated ser-
ine protease, MBL mannose-binding lectin, MCP membrane
cofactor protein, PNH paroxysmal nocturnal hemoglobinuria,
RA rheumatoid arthritis, SLE systemic lupus erythematosus
Classical Pathway
C1, C2 and C4 Deficiency
The first protein in the classical pathway is C1, which com-
prises one C1q molecule, two C1r molecules and two C1s
Fig. 2 Algorithm for complement testing. a Where to start investigating
the possibility of primary immunodeficiency, e.g., infection with
encapsulated organisms. b Where to start if a disease of complement
dysregulation is suspected, such as complement-related kidney disease,
e.g., aHUS. c If not all functions can be tested, do what is available and
proceed to test all possibilities from unavailable pathways. d If multiple
pathways are low, the deficiency likely lies in the shared terminal path-
way. e Activation marker testing can also be helpful to determine if a
component is low due to consumption. If it is a true deficiency then the
cognate fragment would be low or absent with a normal activation marker
level. f When testing for a disease of complement dysregulation, testing
function as well as abundance can help give a more complete picture of
the extent and location of the dysfunction. g Markers of activation to
consider testing include: sC5b-9, C4a, C4d, C3a, C3d, iC3b, C5a, Bb,
Ba and C3 convertase. It is not necessary to measure all markers but by
measuring one in each pathway it is possible to better determine the site of
the dysregulation. For all complement measurement, and activation
markers in particular, proper specimen handling by assay type is key,
including freezing at − 80°C within 2 h of collection. AH50, alternative
pathway hemolytic activity; aHUS, atypical hemolytic uremic syndrome;
AP, alternative pathway; C1-INH, C1 esterase inhibitor; CH50, comple-
ment hemolytic activity; CP, classical pathway; LP, lectin pathway;
MASP, MBL-associated serine protease; MBL, mannose-binding lectin;
PID, primary immunodeficiency. *The samplemay have been improperly
handled, or the patient has autoantibodies against complement
components.
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molecules [10, 19, 63]. C1q binds to the Fc region of IgM and
IgG antibodies and other molecules like CRP bound to target
antigens, e.g., viruses, bacteria or autoantigens. The binding
of more than one C1q head activates C1r, which then cleaves
and activates C1s [21]. Activated C1s cleaves C4 and C2,
leading to the formation of C3 convertase [15]. This causes
large-scale cleavage of C3, and, consequently, the surface be-
comes coated with C3b molecules, while C3a molecules ini-
tiate a localized inflammatory response. IgG subclasses 1 and
3 fix complement more efficiently than IgG2, while IgG4 has
no activity in relation to the complement pathway. Patients
deficient in the initial components of the classical pathway
are prone to autoimmune connective tissue diseases, such as
SLE, and other autoimmune diseases, e.g., dermatomyositis,
Henoch-Schönlein purpura, juvenile rheumatoid arthritis and
glomerulonephritis [64].
Autoimmune manifestations are frequently encountered in
patients with C1q deficiency with approximately 55% fulfilling
the criteria for SLE, a further 22.5% for SLE-like syndrome and
only 7%without evidence of autoimmunity [65]. In individuals
with C1r/C1s deficiency, autoimmune manifestations occur in
60–66% and in 75% of patients with complete C4 deficiency
[26]. The lowest frequency of autoimmunity (10–42%) is ob-
served in C2-deficient patients [26, 66]. Patients with C1, C2 or
C4 deficiency have an increased occurrence of autoantibodies;
antinuclear antibodies are present in 75% of patients with C1 or
C4 deficiency and 25–55% of patients with C2 deficiency.
Anti-dsDNA antibodies are present in 20% of patients with
C1q/C4 deficiency and 33% of patients with C2 deficiency
[26]. There is a high frequency of the C2 null allele in the
Caucasian population (1%) [42]; however, individuals with het-
erozygous C2 or C4 deficiency often remain asymptomatic
[66]. Among individuals with C2 deficiency, the risk of SLE
has been reported to be higher in females than males; the
female:male ratio of 7:1 is comparable with that seen in the
overall population of SLE patients (9:1) [26, 67].
There is an increased incidence of infections in patients
with defects of C1, C2 and C4. It is estimated that ~50% of
patients develop severe bacterial infections including menin-
gitis, pneumonia, osteomyelitis or septicemia. These infec-
tions are caused by encapsulated bacteria, most commonly
Streptococcus pneumoniae. Significant infections were de-
scribed in 29/71 (41%) patients with C1q deficiency [65]
and in 75% of patients with C2 deficiency [66]. These pa-
tients, regardless of the phenotype (autoimmunity or infec-
tion) leading to diagnosis, often experience infection and vas-
cular disease as the leading cause of death [66].
C3 Deficiency
Patients with C3 deficiency are prone to severe infectious
complications, e.g., pneumonia, meningitis, osteomyelitis or
bacteremia caused by encapsulated bacteria, e.g.,Ta
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Haemophilus influenzae and Neisseria meningitidis. These
infections develop early in life and have a tendency to recur
[43, 68]. Patients may also experience membranous glomeru-
lonephritis, while symptoms consistent with SLE are less fre-
quent [69]. Rare C3 gain of function (GoF) mutations may
lead to atypical hemolytic uremic syndrome (aHUS) [70]. One
common and several rare variants in C3 have been associated
with increased risk of AMD [46].
Deficiency of Terminal Components
Terminal components are shared by the classical, lectin and
alternative pathways and are ultimately responsible for the
formation of the MAC [71]. The risk of developing meningo-
coccal meningitis is markedly higher in people who have a
deficiency of one terminal component compared with the gen-
eral population, ranging from 1400 times in patients with C9
deficiency to 7000–10,000 times in those with other terminal
component deficiencies [43]. In contrast to the immunocom-
petent population (median age for meningococcal infection:
3 years), the onset of symptoms in patients with terminal de-
ficiencies is 17 years. However, infections generally lead to
lower mortality and have a milder course than in immunocom-
petent persons [42, 43]. Disseminated Neisseria gonorrhoeae
infections have also been described [42]; however, increased
frequency of other bacterial infections is not observed. A ter-
minal component deficiency is more likely if there is a family
history of meningococcal infections or repeated neisserial in-
fections or if the causative meningococcal serotype is W-135,
X, Y or Z, which less frequently cause infections in healthy
individuals.
Alternative Pathway
The alternative pathway is a highly conserved surveillance
system that is continuously turning over (tick-over) due to a
labile thioester bond in C3 and thus does not require antibod-
ies or lectins for activation [21]. Properdin is a positive regu-
lator of alternative pathway activity and works by stabilizing
alternative pathway convertases [11, 72]. Properdin deficiency
is a rare, hereditary, primary immunodeficiency (total number
of known cases globally > 100) and is the only X-linked com-
plement deficiency [72]. These patients are unusually suscep-
tible to Neisseria infections [72, 73]. It manifests with either
complete absence of the molecule (type I), partial deficiency
(type II) or a normal level of dysfunctional protein (type III).
Properdin-deficient individuals are susceptible to meningo-
coccal disease, which is frequently complicated by sepsis
and most commonly occurs in adolescence [48]. The risk of
meningococcal infection in healthy individuals is usually
greatest in children aged less than two years, when protective
antibodies against meningococcal serotypes have not
developed. In patients with properdin deficiency, the median
age at the time of meningococcal infection is much higher at
approximately 14 years of age [74].
Although the risk of contracting meningococcal infection is
significantly higher in individuals with properdin deficiency, not
all will experience meningococcal infection during their lifetime
[75]. Interestingly, a case of complete deficiency of factor D (FD)
(autosomal recessive inheritance) was described in an adult with
a history of Neisseria meningitidis infections following two ep-
isodes of disseminated gonococcal infection [76]. A familial case
was reported in 2018, where members of the family had normal
levels of factor D (FD) with decreased functionality due to a
missense mutation [77]. In 2013, a 32-year-old woman with
recurrent pneumococcal and meningococcal infection was diag-
nosed with factor B (FB) deficiency [78].
aHUS is a thrombotic microangiopathy characterized by he-
molytic anemia, thrombocytopenia and renal failure, which oc-
curs in the absence of its usual cause (infection with a shiga
toxin-producing organism). aHUS is caused by primary factors
such as mutations in complement genes and autoantibodies
against complement regulatory proteins or secondary causes
such as infection, drug toxicity or autoimmune disorders [79,
80]. Approximately 50–60% of cases of aHUS have an under-
lying genetic component that typically involves genes that reg-
ulate the AP:FH (20–30% of cases), factor I (FI) (5–10%), FB
(1–4%), membrane cofactor protein (MCP)/CD46 (10–15%),
thrombomodulin (3–5%) and C3 GoF (2–10%) [16, 70].
Approximately 20% of patients with aHUS have mutations in
more than one gene [81], and patients with autoantibodies to
regulatory proteins also comprise a significant subset. The ma-
jority of aHUS cases are sporadic and occur in the absence of
prior family history. Furthermore, even in familial forms of
aHUS, penetrance is incomplete [19].
Dysregulation of the alternative pathway appears to also play
a significant role in the pathogenesis of AMD, which is the most
common cause of vision loss in developed countries [82].
Various complement proteins and their activation products and
regulators have been identified in the retinal deposits of patients
with AMD. Pathology-driving polymorphisms in genes
encoding for proteins of the complement system, particularly
FH but also C3 and FI, have been associated with AMD [83].
Lectin Pathway
Lectin
The lectin pathway is focused on the recognition of repet-
itive carbohydrate patterns found on the surface of micro-
bial pathogens. Lectin pattern recognition molecules
(PRMs), which include MBL, ficolin-1, ficolin-2,
ficolin-3, collectin-10 and collectin-11, activate the path-
way in an analogous manner to antibodies in the classical
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pathway [11, 84–86]. MASPs, which act in a similar fash-
ion to C1r and C1s, associate with MBL and activate C4
and C2 by proteolytic cleavage (Fig. 1) [14, 84].
Polymorphisms in the collectin and ficolin genes cause
variable degrees of insufficiency and decreased serum con-
centrations [87]. Lectin pathway impairment due to insuffi-
cient production of any of these components is common and
may be associated with no clear clinical phenotype, mild,
incrementally or somewhat increased risk of infection [88]
especially in young children and otherwise immunosup-
pressed individuals. There are likely to be other factors in-
volved in defining severity, given that deficiencies in the
lectin pathway or MBL alone did not decrease life span in
large population-based studies [2]. Complete ficolin-3 (or
H-ficolin) deficiency was initially associated with increased
susceptibility to infections and necrotising enterocolitis.
Due to its rarity, it is still unclear whether it is a life-
threatening condition with variable penetrance or acts as a
disease modifier [89]. Partial ficolin-2 (or L-ficolin) and
ficolin-3 (or H-ficolin) insufficiencies are not well studied
and are of uncertain clinical significance [90, 91].
MBL
Among Caucasian populations, around 5–7% of people have
inherited MBL deficiency (defined as less than 100 ng/mL)
[13], although this threshold varies between countries/institu-
tions) and does not affect overall mortality or increase suscep-
tibility to community-acquired pneumonia [2]. However,
MBL insufficiency is, in combination with other factors, ob-
served in more severe forms of sepsis and fatal outcomes,
irrespective of the causal microorganisms [92]. Low cord-
blood MBL levels are weakly associated with respiratory
symptoms during infancy [93]; however, MBL2 polymor-
phisms do not increase the risk of mortality following invasive
meningococcal infection in children [94]. MBL insufficiency
has been associated with increased frequency of pyogenic
infections and/or heightened risk of sepsis in infants in some
studies, as well as neutropenic patients undergoing chemo-
therapy and organ transplant recipients [88, 95, 96]. MBL2
polymorphisms may also be associated with increased suscep-
tibility to recurrent infection with herpes simplex virus 2.
MBL recognizes HSV, suggesting that MBL deficiency may
be associated with frequently recurring HSV2 [97, 98]. A
moderately-increased risk of acquisition or progression of oth-
er chronic viral diseases, chronic pulmonary aspergillus infec-
tions and severe malaria have also been previously associated
with MBL insufficiency [88]. Conversely, low levels of MBL
may confer resistance against mycobacteria [99]. MBL poly-
morphisms can also affect susceptibility to SLE and the risk of
infection during treatment [100]; however, the role of MBL
polymorphism in disease remains controversial.
MASP1
MBL-associated serine protease 1 (MASP1), the most abun-
dant protease of the lectin pathway, has a central role in path-
way activation via MASP2. Several mouse models have
shown links between MASP1 and coagulation, renal, gastro-
intestinal and myocardial ischemia/reperfusion-related pathol-
ogy; however, as yet, there is no firm evidence for this type of
pathology in humans [101, 102].
Malpuech, Michels and Mingarelli-Carnevale (3MC) syn-
drome is characterized by facial dysmorphia and other devel-
opmental defects such as cleft lip and palate, postnatal growth
deficiency, cognitive impairment and hearing loss [13, 90, 91,
103]. It is caused by homozygous mutations in the MASP1
gene (3MC syndrome 1) or members of the collectin subfam-
ily COLEC10 or COLEC11 (3MC syndrome 2) [103]. Excess
or unusual infections and autoimmunity have not yet been
described in this syndrome.
MASP2
Severe MASP2 insufficiency was first observed in a single
individual, together with anti-C1q autoantibodies, recurring
pneumonia, pulmonary fibrosis, ulcerative colitis and erythe-
ma multiforme bullosum [104]. The frequency of MASP2
insufficiency caused by genetic polymorphisms is about 4%
in Caucasians and up to 18% in some African populations
[105]. However, most MASP2-insufficient individuals are
asymptomatic. MASP2 insufficiency has also been associated
with increased risk of fever and neutropenia in pediatric pa-
tients undergoing chemotherapy [106]. A meta-analysis
showed that a common polymorphism that affects serum
levels of MASP2 was not associated with the development
of infectious disease [107] Additionally, MASP2 deficiency
may be associated with prematurity and low birthweight but
not with perinatal infections [91].
Deficiencies of Complement Regulation
The complement system has several levels of regulation at the
initiation, amplification (formation of convertases) and mem-
brane attack phases, thereby preventing inadvertent tissue
damage [15, 108]. Deficiency of complement inhibitors leads
to dysregulation either in the fluid phase or on cell surfaces
and consequent recurrent infections (mostly bacterial), inflam-
matory disorders and presentations with a broader clinical
phenotype. These include angioedema (C1 inhibitor [C1-
INH] deficiency), kidney and eye diseases (FH, FI or CD46
deficiency), protein-losing enteropathy (CD55 deficiency)
and paroxysmal nocturnal hemoglobinuria (PNH) (CD55 +
CD59 deficiency) [1, 108, 109]. It is important to note that,
in contrast to complete deficiencies of complement regulatory
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proteins that result in consumption of multiple components in
a pathway, haploinsufficiency can cause excessive local in-
flammation occurring at sites of tissue injury or debris accu-
mulation [110]. For example, haploinsufficiency of FH pre-
disposes to aHUS and AMD [111–116], while homozygous
FH deficiency results in alternative pathway activation, cleav-
age and consumption of C3 and FB and increased susceptibil-
ity to pyogenic infections. Heterozygous deficiency of FI is
also associated with both aHUS and AMD [112, 113].
Haploinsufficiency (50% of normal functional capacity) of
complement regulators creates a “hyperinflammatory” pheno-
type driven by the feedback loop of the alternative pathway
(Fig. 1), sometimes described as the complement
inflammasome. Loss of function in a plasma or membrane
inhibitor of the alternative pathway results in excessive acti-
vation of complement on the endothelium of the kidney in
aHUS and, in AMD, the accumulation of retinal debris within
drusen and complement-mediated inflammation.
In aHUS, the disease commonly presents due to
haploinsufficiency of one of three complement regulators
FH, MCP or FI. Several mechanisms have been described,
the loss of functional capacity due to haploinsufficiency itself
and autoantibodies, which block regulatory proteins (autoan-
tibodies against FH occur in 10% of adult aHUS cases). For
reasons that are not fully understood, autoantibodies usually
develop against a background of deletion of complement FH
related protein (CFHR) 1 and CFHR3 (Table 1). In addition,
the C3 and C5 convertases of the AP can be stabilized (with a
prolongation of half-life) due to mutations in C3 or FB, most
occurring in the binding site. Lastly, polymorphisms in non-
coding regions of complement regulators may predispose to
disease secondary to effects on expression; however, further
studies are needed to demonstrate this definitively [110].
Deficiency of C1-INH results in episodic angioedema
without urticaria that is inherited (hereditary angioedema
(C1-INH-HAE) or acquired (C1-INH-AAE) [117, 118]. In
addition to its role as an inhibitor of C1r and C1s of the clas-
sical pathway and MASP1 and MASP2 of the lectin pathway,
C1-INH is the major inhibitor of factor XIIa and kallikrein.
The lack of inhibition of these enzymes results in excessive
bradykinin generation, which, in turn, increases vascular per-
meability, leading to angioedema [118, 119]. However, a
number of patients suffering from angioedemawithout wheals
present with normal C1-INH levels. Mutations in factor XII
(FXII), plasminogen (PLG), angiopoietin-1(ANGPT1) and
kininogen-1 (KNG1) have been found in this newly-defined
group of primary angioedema patients with normal C1-INH
(nlC1-INH) [120]; however, a significant proportion does
not have a defined molecular explanation as of yet (HAE-
unknown) [121, 122].
FH and FI are key regulators of the AP. Deficiency of either
of these regulators is associated with recurrent infections and
results in uncontrolled activation of the AP with subsequent
secondary C3 deficiency and a reduction in circulating FH
levels (when FI is deficient) [123, 124]. Distinct clinical man-
ifestations have been associated with mutations in several
complement components. Approximately 50% of patients
with aHUS have genetic mutations of FH, FI, C3, FB and/or
MCP and deletion of complement FH-related proteins 1 and 3
(CFHR1/CFHR3) [109]. Thrombomodulin also has a regula-
tory role and binds to FH and C3b thereby inhibiting comple-
ment activation [125]. Interestingly, mutations in FH, MCP
and FI have also been reported in C3 glomerulopathy (former-
ly known as membranoproliferative glomerulonephritis,
MPGN) [109], as well as pre-eclampsia [126] and hemolysis,
elevated liver enzyme levels and low platelet levels (HELLP)
syndrome [127]. Partial FI deficiency has also been previously
associated with clinical manifestations including recurrent
tonsillitis, urinary infections, otitis, pyelonephritis, severe
meningitis and sepsis [128].
Decay accelerating factor (CD55) is a membrane-bound reg-
ulator that dissociates both classical and alternative C3
convertases. CD59 is the key membrane regulator of the termi-
nal pathway that prevents insertion of theMAC into host tissue.
Somatic mutations in the phosphatidylinositol glycan class A
(PIG-A) gene coding for the anchoring structure of both inhib-
itors leads to PNH [129]. Isolated congenital CD55 deficiency
is rare but has been observed in patients suffering from severe
early-onset protein-losing enteropathy [130], whereas severe
Guillain-Barré-like neurological symptoms with hemolysis are
the hallmark of isolated CD59 deficiency [131].
Management and Treatment of Complement
Deficiencies
Recognition of the following warning signs may help clini-
cians in the diagnosis of complement deficiencies [1]:
& Meningococcal meningitis at > 5 years of age
& Recurrent systemic bacterial infections with encapsulated
organisms (particularly Streptococcus pneumoniae and
more rarely gonococcal disease)
& Autoimmune diseases (particularly SLE)
& Angioedema without urticaria
& Inflammatory disorders involving the kidney or eyes
& Unusual infections, e.g., epiglottitis despite vaccination
against Haemophilus influenzae type b (HIB)
& Severe infection with encapsulated bateria
Recurrent infections with encapsulated bacteria, especially
pneumococcus as well as neisserial infection, should alert cli-
nicians to early or late complement component deficiencies,
respectively [132], while renal disorders such as aHUS and
MPGN may suggest dysregulation of the AP [7].
Autoimmune manifestations are generally associated with
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early classical pathway component deficiencies, while angio-
edema without urticaria should alert the clinician to investi-
gate C1-INH deficiency [49]. Immunologists should help
raise awareness of these rare disorders among generalists
and specialists, and diagnosed patients should receive educa-
tion about how to recognize complications and when to seek
medical attention.
It is important to note that similar management principles
for the prevention or treatment of infection may apply in set-
tings where complement deficiency is secondary to a targeted
complement inhibitor such as eculizumab (anti-C5 mAb) or
consumption of C3 that occurs in the presence of C3 nephritic
factor.
Except for HAE, replacement therapy has never reached
routine clinical practice, in part due to rapid metabolism of
complement proteins. Approaches to the management of com-
plement deficiencies depend on the specific disease involved.
Ongoing Management and Family Assessment
Obtaining a detailed family history is useful for the diagnosis
and management of complement deficiencies associated with
immunodeficiency. Most heritable complement deficiencies
are autosomal recessive, and carriers are asymptomatic.
Exceptions include X-linked properdin deficiency and auto-
somal dominant FB, C1-INH and MCP/CD46 deficiencies
and with haploinsufficiency of complement regulatory pro-
teins (FH, FI) [1]. Testing of siblings and other potentially
affected family members is recommended as relatives benefit
from the same preventive care as patients. There are several
important points to consider regarding education of the patient
and family to ensure optimal care and management:
& How often patients should be followed up
& Annual follow up is recommended following diagnosis of
a complement deficiency in order to provide education,
up-to-date advice on appropriate vaccination, antibiotics as
needed, advice for emergencies and family studies as needed
& The potential use of MedicAlert® or similar bracelets to
facilitate early recognition of the underlying disorder if
patients become unwell
& The MedicAlert® website has more information on how
to join and ensure fast, accurate treatment in an emergency
(https://www.medicalert.org/)
& Guidance for patients regarding pregnancy, travel and sur-
gical procedures etc.
& In pregnancy, complement deficiency can increase the risk
of preeclampsia [133]
& During pregnancy, patients should have up-to-date vacci-
nations (if not already vaccinated) and an emergency plan
in place in the event of infection. Patients should be in-
formed about inheritance of complement deficiencies and
any subsequent testing that may be needed
& It is recommended that patients talk to their immunology
health team at least three months before they travel. They
will be able to advise the patient which vaccinations they
might need and what medication to take with them [134,
135]
& It is recommended that patients with complement defi-
ciency be closely monitored following surgery with early
recourse to assessment and antibiotic treatment. In a study
of 538 splenectomised patients, 38 patients developed
bacteremia during the first month after surgery [42, 136]
& In addition, pre-procedural prophylactic administration of
C1-INH concentrate is recommended for HAE patients
undergoing surgical and dental procedures [49]
& Estrogen may exacerbate angioedema attacks in HAE and
patients should be advised to avoid combined contracep-
tives and hormonal replacement therapy [49]
& Agree an emergency plan in the event of infection and
inform the other clinical teams involved in primary and
secondary care. This plan may involve early recourse to
medical attention and an emergency supply of antibiotics
& Complement-deficient patients are at increased risk of in-
fection; therefore, it is of paramount importance to explain
to patients their predisposition to infection and the impor-
tance of preventative immunisations and prompt recourse
to antibiotic therapy in line with their emergency plan
Vaccinations
In patients with complement deficiency, the same vaccines are
recommended as in healthy individuals, with particular em-
phasis on conjugated vaccines against pneumococcus,
Haemophilus influenzae and Neisseria meningitidis [137,
138]. Unconjugated polysaccharide vaccines do not elicit a
memory response and are not immunogenic in children under
the age of 2 years [42]. Inducing and maintaining humoral
immunity through vaccination enhances host defenses where
complement is lacking [139]. The tetravalent conjugate vac-
cine against the serogroups A, C, Y and W of Neisseria
meningitidis is strongly recommended for patients with com-
plement deficiencies [1, 18, 42, 140], together with the me-
ningococcal B vaccine [140]. Contacts should also be vacci-
nated [138, 141]. No vaccines are contra-indicated in patients
with complement deficiencies, meaning that live vaccines can
be administered. The efficacy of vaccines in patients with
complement deficiencies has not been evaluated in large
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cohort studies; however, vaccinations are recommended by
the Advisory Committee on Immunization Practices [138,
142]. Guidelines change frequently with accumulating expe-
rience and are best accessed in real time. C3 is the major
opsonin in the complement pathway; deficiency of which
can result in an increased susceptibility to invasive pneumo-
coccal infections and recurrent pyogenic infections [143]. In
addition to the vaccination advice above, there is a need to
identify low pneumococcal antibody levels in patients with C3
deficiency or rare C3 deficiency syndromes, e.g., C3 nephritic
factor and FH deficiency. This facilitiates appropriate, individ-
ualized booster vaccinations with conjugate or polysaccharide
pneumococcal vaccines.
We recommend monitoring vaccine responses where pos-
sible and administering boosters depending on the durability
of protective antibody levels.
For patients with HAE who may require blood products as
part of their therapy, hepatitis B vaccination is recommended.
Antibiotics
The use of antibiotic prophylaxis in complement deficiencies
is aimed at protecting against infection by encapsulated organ-
isms, and it is best reserved for patients exhibiting recurrent
infections despite appropriate vaccination [18, 42]. This ap-
proach was supported in a prospective study of patients with
homozygous C6 deficiency and recurrent infections living in
an area with endemic group B meningitis, where the use of
monthly benzathine penicillin protected against further
neisserial infections [42]. For patients not considered to re-
quire a prophylactic regimen, it is advisable to ensure access
to emergency antibiotics and prompt medical review as part of
their emergency plan for encapsulated bacterial infections.
Importantly, patients with C3, FH or FI deficiency who have
been vaccinated against meningococcal disease may still pres-
ent with infections.
In summary, the decision to offer antibiotic prophylaxis
(e.g., penicillin- or macrolide-based) over emergency antibi-
otics should be individualized based on risk stratification.
Patients who have high exposure to bacteria (e.g., those living
in endemic areas or working in high-risk professions such as
nursery care) and have recurrent infectionsmay be selected for
prophylaxis. The benefits of prophylaxis should be balanced
against the risks, such as potential development of resistance
to the antibiotics used.
Complement Inhibitors
Eculizumab is a recombinant humanized monoclonal anti-
body with targeted activity against human C5, which inhibits
the cleavage of C5 and subsequent formation of the MAC [7,
12, 144]. Eculizumab is very effective in the treatment of PNH
and of aHUS, preventing progression to end-stage renal
disease [10, 19, 80]. However, a potential major side effect
is recurrent meningococcal infections, and patientsmust there-
fore receive the meningococcal vaccines prior to initiating
therapy and have access to antibiotic prophylaxis [7]. The cost
of therapy is estimated at $600,000 (approximately €529,000)
per year but must be considered against the costs otherwise
incurred including plasma exchange, hospitalisations, end-
stage renal disease and impaired quality of life [7].
Monitoring of eculizumab includes functional analysis of the
classical complement pathway, alternative pathway and com-
plement activation products including C3d and sC5b–9/TCC
[30]. Only recently, ravulizumab, another humanized mono-
clonal anti-C5 antibody, has been approved for the treatment
of PNH by the US FDA and is currently under regulatory
review in both the European Union and Japan [145]. Phase
3 development of intravenous ravulizumab for the treatment
of aHUS is underway.
Treatment for HAE has improved with the development of
C1-INH replacement as well as other agents designed to over-
come the effects of C1-INH deficiency [12, 144]. C1-INH
therapy is currently available in several formulations includ-
ing intravenous (IV) C1-INH replacement administered pro-
phylactically (Cinryze®), IV C1-INH that is used to treat
acute episodes of facial, abdominal and laryngeal attacks
(Berinert®), IV C1-INH replacement that is used to treat acute
episodes in adults and adolescents (Ruconest®) [146] and
subcutaneous C1- INH that is used for routine prophylaxis
in adolescent and adult patients (Haegarda®) [147].
Alternatives to C1-INH for acute therapy include Icatibant
(Firazyr®, a bradykinin B2 receptor antagonist) and
Ecallantide (Kalbitor®, available in the US), which are both
used for the treatment of HAE [146]. Lanadelumab
(Takhzyro®) is a monoclonal antibody against kallikrein that
received approvals for the prophylactic treatment of HAE in
2018 [148] and approved by the National Institute of Clinical
Excellence (NICE) in 2019 [149]. Tranexamic acid, andro-
gens, fresh frozen plasma and solvent detergent-treated plas-
ma have been historically used in the treatment of HAE; how-
ever, for reasons such as limited efficacy and risks of adverse
events, these agents are no longer recommended except as a
last resort if no better choice is available [49]. The recent
WAO/EAACI guideline includes detailed information regard-
ing the recommended treatments for patients with HAE [49].
Gene Therapy
Gene therapy has been evaluated in preclinical models of
HAE. A one-off intravenous administration of an adeno-
associated virus vector expressing the normal genetic se-
quence of human C1-INH was effective at maintaining a nor-
mal level of circulating C1-INH in mice and is hypothesized
to provide long- term protection from angioedema attacks in
patients with HAE [150].
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Hematopoietic Stem Cell Transplantation (HSCT)
C1q is produced by monocytes in healthy individuals; there-
fore, HSCT serves as a potentially curative intervention for
C1q deficiency. Owing to the scarcity of data, there are no
evidence-based recommendations on how best to use HSCT
in patients with complement deficiencies as further studies are
required. However, several cases have been reported in which
HSCT has resulted in restoration of functional C1q and reso-
lution of SLE symptoms [151, 152]. There have also been
some reports of favorable responses to HSCT in HAE where
hematopoietic production of C1-INH appeared sufficient to
prevent attacks [153, 154] and for alloSCT in acquired angio-
edema [155]. As an alternative to HSCT, combined liver and
kidney transplantation has the potential to correct aHUS if the
proteins encoded by the deficient genes are predominantly
synthesized in the liver, such as FH or FI [156]. Importantly,
management of C1q deficiency should take into account indi-
vidual patient requirements as not all interventions are likely
to be successful for all patients [157].
Conclusion
Knowledge regarding the complexity and clinical implications
of defects in the complement system as well as the effects of
novel therapeutic agents targeting complement continues to
grow. Most complement deficiencies, with certain exceptions,
are rare, and the clinical presentations are protean (e.g., infec-
tions, angioedema and renal, connective tissue, ocular, neuro-
logical, gastrointestinal and hematological diseases).
Challenges are presented by the small numbers of patients with
these deficiencies, but advances are being made in relation to
the availability of diagnostic testing, standardization of comple-
ment testing and next generation sequencing. There is also an
active pipeline of therapies in development for the treatment of
disorders due to complement deficiencies as well as
complement-mediated inflammation. Complement deficiencies
represent an exciting field of medicine that is changing rapidly.
This guideline reflects the evidence available in 2019, and it is
anticipated that updates will be required every 2 to 3 years to
reflect the developing evidence and changing practice.
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